SEC Form 4 · accession 0001654954-18-007119
TG THERAPEUTICS, INC. · TGTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Weiss
Officer — CEO and President
Period of report
Jun 26, 2018
Accepted (ET)
Jun 28, 2018 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001316
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| COMMON STOCKF1,F2,F3 | Jun 26, 2018 | A | 1,018,011 | $0.00 | A | 11,648,805 | I | See Note 3 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects an annual grant of restricted stock pursuant to the Strategic Advisory Agreement with Caribe BioAdvisors, LLC, pursuant to which Mr. Weiss provides the services of Chairman of the Board and Executive Chairman. The restricted shares will vest on the date that the Company's Market Capitalization is $100 million greater than the Market Capitalization on the date of grant.
- F2Included in Mr. Weiss' beneficial ownership are 4,910,010 shares of Common Stock issued to Opus Point Partners, LLC, of which Mr. Weiss is a co-founder, managing partner, and principal and beneficially owns a 50% interest.
- F3The shares are held by Caribe BioAdvisors, LLC, of which Mr. Weiss is the sole member.